Low-dose obinutuzumab for steroid-dependent nephrotic syndrome complicated by recurrent rituximab-induced serum sickness and anti-rituximab antibodies.

• Tác giả: Shuichiro Fujinaga, Mayu Nakagawa, Kanako Saito, Koji Sakuraya, Yoshitaka Watanabe
• Ngôn ngữ: eng
• Ký hiệu phân loại: 070.48346 Journalism
• Thông tin xuất bản: Germany : Pediatric nephrology (Berlin, Germany) , 2025
• Bộ sưu tập: NCBI
• ID: 201236

Tóm tắt

 BACKGROUND: Rituximab-induced serum sickness (RISS) is a rare drug complication in patients with steroid-dependent nephrotic syndrome (SDNS). CASE-DIAGNOSIS/TREATMENT: A 7-year-old boy with SDNS exhibited RISS recurrence 8 days after the third rituximab dose. At that time, the patient's antirituximab antibody (ARA) level was extremely high at >
  5000 ng/mg, and his serum rituximab drug level was undetectable at <
  0.2 μg/mL. Further, the patient had an early relapse with a short B-cell depletion period after the third rituximab dose. To address ARA-mediated rituximab resistance, a single infusion of obinutuzumab at a dose of 300 mg/m CONCLUSIONS: Low-dose obinutuzumab can be an effective and safe option for rituximab-resistant SDNS complicated by RISS and the development of ARA.